Sponsors (4)
Official title: Prohibit pharmacy benefit managers and pharmacies from being under common ownership, and for other purposes.
Introduced May 13, 2026 by Elizabeth Warren · Last progress May 13, 2026
The bill aims to lower drug prices and curb anti‑competitive PBM/pharmacy/insurer behavior by forcing separation and strengthening enforcement, but it risks short‑term disruptions to pharmacy access and raises litigation, compliance, and restructuring costs that could be passed on to consumers.
Patients who buy prescription drugs (including people with chronic conditions, Medicare and Medicaid beneficiaries) could pay lower drug prices because bans on vertical integration and limits on PBM self‑preferencing reduce conflicts of interest and markup behavior.
Consumers harmed by vertically integrated pharmacy/PBM/insurer conduct can recover money — individuals gain clearer private‑suit rights and treble damages and fee awards, improving compensation for overcharges.
State and federal enforcers (FTC, DOJ Antitrust, HHS OIG, state AGs) get clearer authority and stronger remedies (divestiture trustees, escrow, disgorgement) to stop and unwind anti‑competitive ties, improving market oversight.
Insurers, PBMs, and pharmacies face greater private litigation exposure (treble damages and broad suit rights), which could increase legal costs and insurance/compliance expenses that may be passed on to consumers in higher premiums or drug prices.
Patients and some provider networks could experience short‑term access and supply disruptions and worsened care coordination as vertically integrated pharmacies are forced to divest or be sold within tight deadlines.
Divestiture requirements and financial penalties (including escrowing ~10% of profits for missed milestones) create cash‑flow and restructuring burdens on covered companies that could lead to service cutbacks or higher consumer prices.
Based on analysis of 3 sections of legislative text.
Bars any person from owning both a pharmacy and a PBM or insurer, requires divestiture within one year, and creates public and private enforcement with treble damages.
Prohibits any company or person from simultaneously owning or controlling a pharmacy and either a pharmacy benefit manager (PBM) or an insurance company, and requires divestiture of pharmacies within one year of enactment if that dual ownership exists. It gives the FTC, the DOJ Antitrust Division, HHS Office of Inspector General, and state attorneys general authority to enforce the rule, creates a private right of action with treble damages and fees, and establishes milestone guidance, escrow penalties, and trustees to force divestiture when required. The Act is designed to break vertical integration that critics say lets large health conglomerates steer prescriptions to affiliated pharmacies and raise costs, and to protect independent pharmacies, patients, and competition by enabling robust public and private enforcement and transaction review authority.